AUTHOR INDEX
Volume 32
July-December 1985

Abdulla, K.A., 261, 623
Aedo-, A.-R., 581
Althoff, P.-H., 97
Anand, S., 109
Anderson, N.O., 491
Ansari, S., 109
Baker, D.A., 377
Bakri, A., 207
Bamji, M.S., 405
Bardin, C.W., 75
Barnes, R.B., 347
Bauer, L., 183
Benkhamou, E., 553
Bent, A.E., 367
Bhattacharya, K., 517
Brandeis, A., 603
Brenner, P.F., 531
Bygdeman, M., 45
Carroad, E., 497
Casado, M.E., 53, 603
Chandra, H., 283, 483
Chaudhuri, C., 417
Chaudhuri, G., 191
Chen, B.L., 301
Chi, I.-C., 119
Chiang, R.-S., 347
Chowdhury, S.R., 283
Christensen, N.J., 359
Clavel, F., 553
Croxatto, H.B., 53, 603
Dai, M.Z., 301
Dattwyler, R.J., 377
David, G.F.X., 135
Decarli, A., 637
Desai, A.D., 135
Díaz, S., 53, 603
Diczfalusy, E., 1, 323, 581
Diethelm, P., 395
Donaldson, A., 275
Dutta, S.K., 417
Eissa, M.K., 87
Elwan, S.I., 261
Farooq, A., 109
Fasoli, M., 637
Feldblum, P.J., 445
Feng, D., 455
Flamant, R., 553
Foldesy, R.G., 267
Franceschi, S., 637
Frick, J., 661
Gahn, G., 97
Gambone, J.C., 191
Giner, J., 149
Goldzieher, J.W., 33
Gu, Y., 491
Guha, S.K., 109
Hahn, D.W., 267, 311
Hameed, C., 377
Hellberg, D., 337
Hendrickx, A.G., 497
Herreros, C., 53, 603
Hetyei, N.S., 311
Hingorani, V., 429
Holck, S.E., 395
Holma, P., 163
Homm, R.E., 267
Indian Council of Medical Research Task Force on Hormonal Contraception, 383
Iohan, F., 571
Jackanicz, T.M., 571, 603
Jacob, C.M., 405
Jeffcoate, S.L., 275
Jensen, B.M., 23
Johannisson, E., 581
Johnston, D.W., 367
Juez, G., 53, 603
Kabir, S.N., 517
Kainz, P., 661
Kamboj, V.P., 283, 517
Kaminski, J.M., 183
Karnik, P.O., 135
Kazi, A., 395
Killinger, J., 311
Kinra, G., 429
Klufio, C., 445
Kühl, C., 23
Kuhl, H., 97
Kumar, T.C.A., 135
Ladishenskaya, A., 75
Lamptey, P., 445
Langren, B.-M., 581
La Vecchia, C., 637
Lea, R.H., 367
Limonta, P., 75
Ling, W.Y., 367
Liu, C.Q., 301
Lobo, R.A., 347

Louis, S.M., 199
Lozano, M., 149
Macri, C., 191
Madhavapeddi, R., 437
Maggs, J.L., 173
Malaviya, B., 283
Maskati, B.T., 135
Matrljan, I., 253
Mauvais-Jarvis, P., 553
McGuire, J.L., 311
Milch, P., 377
Miranda, P., 53, 603
Mishell, D.R., Jr., 531
Misro, M.M., 109
Mølsted-Pedersen, L., 23
Monder, C., 571
Monheit, A.G., 377
Mukherjea, M., 417
Nair, K.M., 473
Negri, E., 637
Newburger, J., 33
Newton, J.R., 87
Nielsen, J., 23
Nigam, P.K., 283, 483
Nilsson, S., 337
Nussbaumer-Kainz, V., 661
Nuzzo, N.A., 183
Pakrashi, A., 517
Pal, A.K., 517
Pampallona, S., 637
Pardridge, W., 191
Park, B.K., 173
Pavlou, S., 75
Pearce, S., 275
Pearson, R.M., 199
Pedrón, N., 149
Peralta, O., 53, 603
Phillips, A., 311
Prahalada, S., 497
Prasad, K.V.S., 473
Prasad, S., 429
Prema, K., 405
Pruyn, S., 191
Ramachandran, P., 437
Randic, L., 253
Rani, M., 405
Rao, B.S.N., 473
Robertson, D.N., 163
Rogers, S., 119
Romberg, G., 97
Ruangsomboon, O., 217
Salem, H.S., 261
Salem, H.T., 623
Salvatierra, A.M., 53, 603
Samyukta, D., 405
Schiapacasse, V., 603
Scott, J.Z., 367
Sedee, A.G.J., 207
Shaaban, M.M., 261, 623
Shah, R.S., 135
Sharma, D.N., 109
Shen, S.R., 301
Shi, X.-Q., 651
Shoupe, D., 347, 531
Sitruk-Ware, R., 553
Sivakumar, B., 473
Skouby, S.O., 23
Smith, S.C., 445
Sparks, R.A., 87
Sufi, S.B., 275
Sun, Y.-B., 651
Sundaram, K., 75
Svenstrup, B., 23
Swahn, M.-L., 45
Tarazona, M., 149
Taubert, H.-D., 97
Tejani, N., 377
Thau, R.B., 75
Thomas, J., 377
Toddywalla, V., 135
Toews, M.R., 367
Valentin, J., 337
Van Henegouwin, G.M.J.B., 207
Visutakul, P., 217
Vlasic, S., 253
Waller, D.P., 183
Wang, C., 237
Wang, Y., 651
Waszak, C.S., 253
Wilkens, L., 119
World Health Organization
Task Force on Oral
Contraceptives, 223
Xiao, B., 455
Xing, S., 581
Yeung, R.T.T., 237
Zamora, G., 149
Zaneveld, L.J.D., 183
Zhang, G.Z., 301
Zhang, X., 455

SUBJECT INDEX

Volume 32

July to December 1985

Abortifacients, status report, 1
Abortions and births, estimate of numbers, 1
[Ac-D-NAL(2)^1, 4FD-Phe^2, D-Trp^3, D-Arg^6]-GnRH species differences in sensitivity (mouse, rat, rabbit), 75
Acceptability, intranasal administration of norethisterone, 135
d-17 β-Acetoxy-13 β-ethyl-17-ethynyl-4-gonen-3-one oxime; ORF 10131 (norgestimate)
Adrenal gland development, effect of exposure to medroxyprogesterone acetate during gestation (baboon), 497
Adrenal gland weight, effect of gossypol (rat), 491
AF-45 (2 α,17 α-diethynyl-A-Nor-5 α-androstane-2 β,17 β-diol), effect on implantation (rat), 301
Age structure of population, 1
Age-standardized risk ratios of breast cancer, oral contraceptive users and nonusers, 553
Albumin level, effect of combined oral contraceptives, 223
Alcohol consumption, effect of relative risk estimate of induced abortion, 637
Alkaline phosphatase level, effect of combined oral contraceptives, 223
Anordrin (2 α,17 α-diethynyl-A-Nor-5 α-androstane-2 β,17 β-diol-diproprionate),
  antifertility effect (rat), 301
  transformation (rat), 301
Antifertility activity,
  nonoxynol-9 (rabbit), 267
  ORF 13904 (rabbit), 267
Aryl 4-guanidinobenzoates, vaginal contraceptive activity (rabbit), 183
Aspartate aminotransferase level, effect of combined oral contraceptives, 223
Barrier methods, status report, 1
Benign breast disease history, effect on realtive risk of breast cancer among oral contraceptive users vs. nonusers, 553
Biliary and urinary metabolites of ethynylestradiol, 173
Bilirubin level, effect of combined oral contraceptives, 223
Bioactive LH level, effect of nafarelin acetate, 347
Biochemical parameters,
  effect of ethinyl estradiol + levonorgestrel, 223
  effect of ethinyl estradiol + norethisterone, 223
  effect of IUD, 223
Biochemical profile, effect of vitamin supplements with administration of ethinyl estradiol + d-norgestrel, 405
Births and abortions, estimate of numbers, 1
Bleeding,
  following intramuscular sulprostone, 429
  following vacuum aspiration, 429

Bleeding pattern,
effect of nafarelin acetate, 531
norethisterone enanthate, 395
use of copper T 200, 603
use of copper T 380 Ag, 53, 623
use of Norplant® subdermal implants, 53, 623
use of progesterone-releasing vaginal rings, 603
use of vaginal ring releasing levonorgestrel, 455, 581
Blood loss, effect of sulprostone prior to vacuum aspiration, 359
Blood pressure,
effect of estradiol cypionate + norethisterone oenanthate, 383
effect of estradiol valerate + norethisterone oenanthate, 383
effect of nonalkylated estrogen/progestogen compound in diabetic women, 23
effect of norethisterone oenanthate, 383
effect of vasectomy, 149
Body weight,
effect of estradiol cypionate + norethisterone oenanthate, 383
effect of estradiol valerate + norethisterone oenanthate, 383
effect of gossypol (rat), 491, 651
effect of norethisterone oenanthate, 383
effect of polyvinylpyrrolidone-gossypol (rat), 651
effect of vasectomy, 149
Breast cancer and oral contraceptives, 553
Breast enlargement in breast-fed girl, mother used ethinyl estradiol + d-norgestrel, 437
Breast-fed child, breast enlargement in girl whose mother used ethinyl estradiol + d-norgestrel, 437
Breastfed infants, immunoglobulin levels when mothers used Norplant®, 261
Breastfeeding episodes and supplementary feedings,
effect of copper T 380-Ag, 623
effect of levonorgestrel, 623
Breastfeeding status,
effect of copper T 200, 603
effect of copper T 380 Ag, 53
effect of levonorgestrel, 53
effect of progesterone-releasing vaginal rings, 603
Centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-(p-(ß-pyrrolidinoethoxy)-phenyl)-7-methoxychroman),
effect on estrogen-senitive biochemical parameters in genital organs (monkey), 483
effect on steroid and peptide hormones (monkey), 283
Center for Population Research (CPR), 323
Cervical dilatation, effect of sulprostone, 359
Cervical mucus immunoglobulin levels,
combined oral contraceptive users, 87
copper IUD users, 87
Cervical neoplasia and oral contraceptives, 337
Cervix, effect of Centchroman (monkey), 483
Characteristics of women undergoing induced abortion, 637
Chlorhexidine, effect on sperm motility, 199

Cholesterol level,
effect of combined oral contraceptives, 223
effect of subdermal implants releasing levonorgestrel, 163
effect of vasectomy, 149
Cigarette smoking, effect on relative risk estimate of induced abortion, 637
Clinical chemistry,
effect of copper T 380 Ag, 53
effect of Norplant® subdermal implants, 53
Clinical chemistry parameters, effect of vitamin supplements with administration of ethinyl estradiol + d-norgestrel, 405
Clinical pharmacological study, vaginal device releasing levonorgestrel, 581
Clinical tolerance, intranasal administration of norethisterone, 135
Complaints, use of contraceptive vagial tablets, 445
Complications,
following intramuscular sulprostone, 429
following vacuum aspiration, 429
use of sulprostone prior to vacuum aspiation, 359
Contraceptive efficacy, progesterone-releasing vaginal rings, 603
Contraceptive practice, effect on relative risk estimate of induced abortion, 637
Contraceptive vaginal tablets, comparative clinical study, 445
Contragestative agent, flowers of Hibiscus rosa-sinensis (mouse), 517
Copper IUD users, immunoglobulin levels in serum and cervical mucus, 87
Copper T 200, use in nursing women, 603
Copper T-220, expulsion associated with immediate postpartum insertions, 119
Copper T 380 Ag, influence of lactation and infant growth, 53, 623
Cytotoxic effects, photoproducts of irradiated norethisterone, 207
Delta loop, expulsion associated with immediate postpartum insertions, 119
Delta T, expulsion associated with immediate postpartum insertions, 119
Demographic variables, effect on relative risk estimate of induced abortion, 637
Diabetes control, effect of estradiol + estriol + norethindrone, 23
Diabetic women, use of estradiol + estriol + norethindrone, 23
2 α,17 α-Diethynyl-A-Nor-5α-androstane-2 β,17 β-diol (AF-45)
2 α,17 α-Diethynyl-A-Nor-5α-androstane-2 β,17 β-diol-dihemisuccinate (SIPPR-113)
2 α,17 α-Diethynyl-A-Nor-5α-androstane-2 β,17 β-diol-dipropionate (anordrin)
3,4-trans-2,2-Dimethyl-3-phenyl-4-(p-(β-pyrrolidinoethoxy)-phenyl)-7-methoxychroman (Centchroman)
Discontinuation rate,
ethinyl estradiol + levonorgestrel, 223
ethinyl estradiol + norethisterone, 223
IUD, 223
norethisterone enanthate, 395
use of contraceptive vaginal tablets, 445
Discontinuations,
effect of estradiol cypionate + norethisterone oenanthate, 383
effect of estradiol valerate + norethisterone oenanthate, 383
effect of norethisterone oenanthate, 383

use of copper T 200, 603
use of progesterone-releasing vaginal rings, 603
DNA sedimentation pattern, effect of gossypol (rat), 661
DNA synthesis in testis, effect of gossypol (rat), 661
Duration of oral contraceptive use, effect on relative risk of breast cancer among oral contraceptive users, 553
Embryotoxicity, effect of medroxyprogesterone acetate (baboon), 497
Emko vaginal tablets, clinical study, 445
Endometrial histology, effect of norethisterone enanthate, 417
Endometrial morphology, effect of levonorgestrel, 581
Endometrial steroid levels, effect of levonorgestrel, 581
Endometrium,
effect of anordrin (rat), 301
effect of Hibiscus rosa-sinensis flowers (mouse), 517
effect of nafarelin acetate, 531
effect of norgestimate (rabbit), 311
effect of SIPPR-113 (rat), 301
Epidemiological analysis, expulsion associated with immediate postpartum IUD insertions, 119
Epidemiological considerations, relationship between oral contraceptive use and breast cancer, 553
Epididymal weight, effect of mating (rat), 217
Estradiol + estriol + norethindrone, use in diabetic women, 23
Estradiol cypionate + norethisterone oenanthate, clinical trial, 383
Estradiol level,
effect of Centchroman (monkey), 283
effect of ethinyl estradiol + desogestrel, 97
effect of ethinylestradiol + norethindrone, 367
effect of levonorgestrel, 455, 581
effect of nafarelin acetate, 347, 531
effect of nonalkylated estrogen/progestogen compound in diabetic women, 23
effect of norethisterone, 135
effect of triphasic ethinyl estradiol + levonorgestrel, 97
Estradiol level of uterine horn with IUD, effect of indomethacin (rat), 191
Estradiol valerate + norethisterone oenanthate, clinical trial, 383
Estrogen-sensitive biochemical parameters in genital organs, effect of Centchroman (monkey), 483
Estrone level, effect of nonalkylated estrogen/progestogen compound in diabetic women, 23
Estrous cycle, effect of gossypol (rat), 491
Ethinyl estradiol + desogestrel, effect on hormonal and metabolic parameters, 97
Ethinyl estradiol + levonorgestrel,
effect on hormonal and metabolic parameters, 97
effects on biochemical aspects, 223
Ethinylestradiol + norethindrone, effect on gonadotropin and steroid levels, 367
Ethinyl estradiol + norethisterone, effect on biochemical aspects, 223
Ethinyl estradiol + d-norgestrel,
breast enlargement in breast-fed girl whose mother used combination pill, 437
effect of vitamin supplements on clinical and biochemical indices, 405

Ethynyl estradiol,
biliary and urinary metabolites, 173
high performance liquid chromatographic profile, 571
measurement of concentration released when incorporated into Silastic formulations, 571
pharmacokinetics, 33
Expulsions in immediate postpartum insertions, Lippes loop D, copper T-220, Delta T and Delta loop, 119
Fertility,
after IUD removal, 253
effect of gossypol (rat), 651
effect of polyvinylpyrrolidone-gossypol (rat), 651
Fertility regulating methods, estimated worldwide use, 1
Fertility regulation,
choice of various methods, 1
present and future, 1
Fertility regulation in nursing women, 53, 603
Fertilization,
effect of aryl 4-guanidinobenzoates (rabbit), 183
effect of nonoxynol-9 (rabbit), 183
First full term pregnancy, effect on relative risk of breast cancer among oral contraceptive users vs. nonusers, 553
Ford Foundation, research and training in reproductive sciences, 323
FSH (follicle stimulating hormone)
FSH level,
effect of Centchroman (monkey), 283
effect of ethinylestradiol + norethindrone, 367
effect of GnRH agonist (mouse, rat, rabbit), 75
effect of nafarelin acetate, 347, 531
effect of norethisterone, 135
Funding of research on fertility regulatng methods, status report, 1
Gastrin level,
effect of ethinyl estradiol + desogestrel, 97
effect of triphasic ethinyl estradiol + levonorgestrel, 97
Genital infectious diseases, effect on relative risk estimate of induced abortion, 637
Genitalia of fetuses, effect of exposure to medroxyprogesterone acetate during gestation (baboon), 497
Genitalia of infants, effect of exposure to medroxyprogesterone acetate during gestation (baboon), 497
Glucose excretion, effect of nonalkylated estrogen/progestogen compound in diabetic women, 23
Glucose level,
effect of combined oral contraceptives, 223
effect of ethinyl estradiol + desogestrel, 97
effect of nonalkylated estrogen/progestogen compound in diabetic women, 23
effect of triphasic ethinyl estradiol + levonorgestrel, 97
Glycosylated hemoglobin level, effect of nonalkylated estrogen/progestogen compound in diabetic women, 23
GnRH (gonadotropin-releasing hormone)
GnRH agonist,
[Ac-D-NAL(2)^{1},4FD-Phe^{2}, D-Trp^{3},D-Arg^{6}]-GnRH, 75
nafarelin acetate, 347, 531

Gossypol,
antifertility effect (rat), 651
effect on estrous cycle and ovarian weight (rat), 491
effect on LH-stimulated testosterone production by Leydig cells (mouse), 275
effect on macromolecular synthesis in testis (rat), 661
effect on testosterone production by Leydig cells (mouse), 275
effect on viability of Leydig cells (mouse), 275
Gossypol and hypokalaemia, 237
Gossypol-related hypokalaemia,
clinical studies, 237
extent of problem, 237
possible mechanisms, 237
studies in animals, 237
Haematological indices, effect of norethisterone enanthate, 417
Haemoglobin concentration, effect of norethisterone enanthate, 417
HCG (human chorionic gonadotropin)
HCG level, effect of sulprostone, 429
Height of breastfed infants,
effect of copper T 380-Ag, 623
effect of levonorgestrel, 623
Helper cells, effect of oral contraceptives, 377
Hemoglobin concentration, effect of nafarelin acetate, 531
Hibiscus rosa-sinensis flowers, effect on implantation (mouse), 517
Hormonal considerations, relationship between oral contraceptive use and breast cancer, 553
Host risk factors, effect on expulsion associated with immediate postpartum IUD insertions, 119
17 β-Hydroxy-11 β(4-dimethylaminophenyl-1)-17 α(prop-1-ynyl)-estra-4, 9-dien-3-one (RU 486)
Hypokalaemia, causes, 237
Hypokalaemia and gossypol, 237
Hypokalaemia in clinical practice, 237
Hypokalaemic periodic paralysis, 237
Immunoglobulin levels, effect of levonorgestrel, 261
Immunoglobulin levels in serum and cervical mucus,
combined oral contraceptive uses, 87
copper IUD users, 87
Immunological approaches to fertility regulation, status report, 1
Immunoreactive LH level, effect of nafarelin acetate, 347
Implantation,
effect of AF-45 (rat), 301
effect of anordrin (rat), 301
effect of Hibiscus rosa-sinensis flowers (mouse), 517
effect of SIPPR-113 (rat), 301
Indomethacin, effect on estradiol level of uterine horn with IUD (rat), 191
Induced abortion, characteristics of women, 637
Infant growth, effect of levonorgestrel administration to breastfeeding women, 53, 623
Infertility, status report, 1

Injectable contraceptive,
estradiol cypionate + norethisterone oenanthate, 383
estradiol valerate + norethisterone oenanthate, 383
medroxyprogesterone acetate, 497
norethisterone enanthate, 383, 395, 417
Insertion method, effect on expulsion associated with immediate postpartum IUD insertions, 119
Insertor's experience, effect on expulsion associated with immediate postpartum IUD insertions, 119
Insulin requirements, effect of nonalkylated estrogen/progestogen compound in diabetic women, 23
International Committee for Contraception Research (ICCR), 323
International Conference on Primary Health Care, 323
International Planned Parenthood Federation (IPPF), 323
Intra-vas deferens injection, pH lowering polymer (monkey), 109
Intranasal contraceptive,
nafarelin acetate, 347, 531
norethisterone, 135
Intrauterine device (IUD),
copper, 87
copper T 200, 603
copper T-220, 119
copper T 380 Ag, 53, 623
Delta loop, 119
Delta T, 119
effect on frequency of cervical neoplasia, 337
effects on biochemical aspects, 223
estradiol level of uterine horn and effect of indomethacin (rat), 191
Lippes loop D, 119
return to fertility after removal, 253
Iron deficiency anemia,
dietary induction (rabbit), 473
effect on pharmacokinetics of levonorgestrel (rabbit), 473
effect on pharmacokinetics of norethisterone (rabbit), 473
IUD (intrauterine device)
IUD design, effect on expulsion associated with immediate postpartum IUD insertions, 119
Lactating women, side effects of oral contraceptive use, 437
Lactation,
effect of levonorgestrel, 53, 623
effect of progesterone-releasing vaginal rings, 603
Levonorgestrel,
effect of iron deficiency anemia on pharmacokinetics (rabbit), 473
effect on cholesterol and HDL-cholesterol concentrations, 163
effect on immunoglobulin levels, 261
high performance liquid chromatographic profile, 571
influence on lactation and infant growth, 53
measurement of concentration released when incorporated into Silastic formulations, 571
pharmacokinetic and pharmacodynamic studies, 455, 581
progesterone receptor studies, 311

Levonorgestrel level,
effect of covered rod implants releasing levonorgestrel, 163
effect of Norplant® contraceptive implants, 163
effect of subdermal implants releasing levonorgestrel, 163
use of vagial ring releasing levonorgestrel, 455, 581
Levonorgestrel levels in plasma and milk, use of Norplant® subdermal implants, 53
Leydig cells, effect of gossypol on viability (mouse), 275
LH (luteinizing hormone)
LH level,
effect of Centchroman (monkey), 283
effect of ethinylestradiol + norethindrone, 367
effect of GnRH agonist (mouse, rat, rabbit), 75
effect of levonorgestrel, 455
effect of nafarelin acetate, 347, 531
effect of norethisterone, 135
LH-stimulated testosterone production by Leydig cells, effect of gossypol (mouse), 275
LHRH (luteinizing hormone-releasing hormone)
Life expectancy at birth, 1
Lipid levels, before and after vasectomy, 149
Lipoproteins level, effect on vasectomy, 149
Lippes loop D, expulsion associated with immediate postpartum insertions, 119
Liver weight, effect of gossypol (rat), 491
Lymphocyte subsets, effect of oral contracetives, 377
Macromolecular synthesis in testis, effect of gossypol (rat), 661
Male contraception,
intra-vas deferens injection of pH lowering polymer (monkey), 109
pill for men, 1
Male contraceptive,
gossypol, 237, 275, 651, 661
polyvinylpyrrolidone-gossypol, 651
Mating, effect on sperm count and weight of epididymis (rat), 217
Mating study, effect of intra-vas deferens injection of pH lowering polymer (monkey), 109
Measurement of ethynylestradiol incorporated into sustained release contraceptive formulations, 571
Measurement of levonorgestrel incorporated into sustained release contraceptive formulations, 571
Medroxyprogesterone acetate, embryotoxicity (baboon), 497
Medroxyprogesterone acetate level, administration of medroxyprogesterone acetate druing gestation (baboon), 497
Menses inducers, status report, 1
Menstrual cycle, effect of intranasal administration of norethisterone, 135
Menstrual pattern,
effect of Centchroman (monkey), 283
effect of estradiol cypionate + norethisterone oenanthate, 383
effect of estradiol valerate + norethisterone oenanthate, 383
effect of norethisterone oenanthate, 383
Metabolites of ethynylestradiol, study of biliary and urinary excretion, 173
Milk, levonorgestrel level during use of Norplant® subdermal implants in nursing women, 53

"Mini-megalopolis" number, projected, 1
Morphometric analysis of endometrium, effect of levonorgestrel, 581
Nafarelin acetate ((6-D-[2-naphthyl]-alanyl)-GnRH), effect on ovulation, 531
Nafarelin acetate (D-Nal_2)^6-LHRH), effect on LH bioactivity, 347
(6-D-[2-Naphthyl]-alanyl)-GnRH (nafarelin acetate)
D-(Nal_2)^6-LHRH (nafarelin acetate)
"Natural" familiy planning, status report, 1
Natural killer cells, effect of oral contraceptives, 377
Neo Sampoon, clinical study, 445
New contraceptives for women, status report, 1
Non-esterified fatty acids levels, effect of vasectomy, 149
Non-hormonal observations, use of intranasal nafarelin acetate, 531
Nonoxynol-9,
  antifertility activity (rabbit), 267
  effect on sperm motility, 199
  vaginal contraceptive activity (rabbit), 183
Norethisterone,
  effect of iron deficiency anemia on pharmacokinetics (rabbit), 473
  effects on photodecomposition by UV-B light, 207
  reproductive endocrine efects, 135
Norethisterone enanthate,
  clinical study, 395
  clinical trial, 383
  effect on haematological indices and endometrial histology, 417
Norgestimate (ORF 10131; d-17 β-acetoxy-13 β-ethyl-17-ethynyl-4-gonen-3-one oxime),
  pharmacologic activity, 311
  progestational activity (rabbit), 311
  progestogen receptor studies, 311
  stability studies, 311
Norplant® subdermal implants,
  effect on cholesterol and HDL-cholesterol concentrations, 163
  effect on immunoglobulin levels, 261
  influence on lactation and infant growth, 53, 623
Nursing women, fertility regulation, 53, 603
Oral contraceptive,
  estradiol + estriol + norethindrone, 23
  ethinyl estradiol + desogestrel, 97
  ethinyl estradiol + levonorgestrel, 223
  ethinylestradiol + norethindrone, 367
  ethinyl estradiol + norethisterone, 223
  ethinyl estradiol + d-norgestrel, 405, 437
  triphasic ethinyl estradiol + levonorgestrel, 97
Oral contraceptive use in lactating women, side effects, 437
Oral contraceptive users, immunoglobulin levels in serum and cervical mucus, 87
Oral contraceptives, effect on lymphocyte subsets, 377
Oral contraceptives and breast cancer, 553
Oral contraceptives and cervical neoplasia, 337
ORF 13904,
  antifertility activity (rabbit), 267
  effect on sperm motility, 267
  effect on sperm penetration test, 267

Ortho vaginal tablets, clinical study, 445
Ovarian function, effect of estradiol + estriol + norethindrone, 23
Ovarian reaction, effect of levonorgestrel, 455, 581
Ovarian weight, effect of gossypol (rat), 491
Ovary,
  effect of gossypol (rat), 491
  effect of Hibiscus rosa-sinensis flowers (mouse), 517
Overall risk ratio, breast cancer among oral contraceptive users vs. nonusers, 553
Ovulation,
  effect of GnRH agonist (rat, rabbit), 75
  effect of nafarelin acetate, 531
PG (prostaglandin)
PG analogue,
  16-phenoxy-tetranor-PGE_2 methyl sulfonylamide, 45
  sulprostone, 359, 429
Pharmacokinetic and pharmacodynamic studies, levonorgestrel, 455, 581
Pharmacokinetic parameters,
  levonorgestrel (rabbit), 473
  norethisterone (rabbit), 473
Pharmacokinetic parameters for ethynyl estradiol, reasonable estimate values, 33
Pharmacokinetic parameters in the literature, ethynyl estradiol, 33
Pharmacokinetics, ethynyl estradiol, 33
Pharmacologic activity, norgestimate, 311
16-Phenoxy- ω-17,18,19,20-tetranor-PGE_2 methyl sulfonylamide (sulprostone)
16-Phenoxy-tetranor-PGE_2 methyl sulfonylamide + RU 486,
  effect on early pregnancy termination, 45
  effect on uterine contractility, 45
Photodecomposition by UV-B light, norethisterone, 207
Photoproducts of irradiated norethisterone, study of cytotoxic effects, 207
Pill for men, status report, 1
Planned pregnancy, return to fertility after IUD removal, 253
Polyvinylpyrrolidone-gossypol, antifertility effect (rat), 651
Population Council, 323
Population projections, 1
Population size, projected, 1
Postcoital agents, status report, 1
Postpartum IUD insertion, epidemiological analysis on expulsion, 119
Postpartum use of Norplant®, effect on immunoglobulin levels of mothers and breastfed infants, 261
Pregnancy,
  effect of RU 486, 45
  effect of RU 486 + PGE analogue, 45
Pregnancy outcome, administration of medroxyprogesterone acetate during gestation (baboon), 497
Pregnancy termination,
  evaluation of sulprostone and vacuum aspiration, 429
  use of sulprostone prior to vacuum aspiration, 359

Progesterone level,
effect of anordrin (rat), 301
effect of Centchroman (monkey), 283
effect of ethinylestrdiol + norethindrone, 367
effect of GnRH agonist (rabbit), 75
effect of levonorgestrel, 455, 581
effect of nafarelin acetate,, 347, 531
effect of nonalkylated estrogen/progestogen compound in diabetic women, 23
effect of norethisterone, 135
effect of SIPPR-113 (rat), 301
use of progesterone-releasing vaginal rings in nursing women, 603
Progesterone-releasing vaginal ring, contraceptive efficacy, 603
Progestogen delimma, 581
Progestogen receptor studies,
levonorgestrel, 311
levonorgestrel-3-oxime, 311
levonorgestrel-17-acetate, 311
norgestimate, 311
progesterone, 311
Protein level, effect of combined oral contraceptives, 223
Protein synthesis in testis, effect of gossypol (rat), 661
Psychiatric complaints, effect on relative risk estimate of induced abortion, 637
Rate constants, ethynyl estradiol, 33
Red blood cell count, effect of norethisterone enanthate, 417
Relative risk estimate of induced abortion, characteristics of women, 637
Relative risk of breast cancer, oral contraceptive users vs. nonusers, 553
Removal of IUD, return to fertility, 253
Reproductive endocrine effects, intranasal administration of norethisterone, 135
Reproductive history, effect on relative risk estimate of induced abortion, 637
Return to fertility after IUD removal, 253
Risk of factors for cervical intraepithelial neoplasia, 337
RNA synthesis in testis, effect of gossypol (rat), 661
RU 486 (17 β-hydroxy-11 β(4-dimethylaminophenyl-1)-17 α(prop-1-ynyl)-estra-4,9-dien-e-one),
effect on early pregnancy termination, 45
effect on uterine contractility, 45
RU 486 + PGE analogue,
effect on early pregnancy termination, 45
effect on uterine contractility, 45
Semenology study, effect of intra-vas deferens injection of pH lowering polymer (monkey), 109
Sex and accessory sex organ weights,
effect of gossypol (rat), 651
effect of polyvinylpyrrolidone-gossypol (rat), 651
Sex hormone binding globulin level, effect of nonalkylated estrogen/progestogen compound in diabetic women, 23
Sexual habits, effect on relative risk estimate of induced abortion, 637

Side effects,
    norethisterone enanthate, 395
    oral contraceptive use in lactating women, 437
    use of coper T 200, 603
    use of intranasal nafarelin acetate, 531
    use of progesterone-releasing vaginal rings, 603
    use of sulprostone, 429
    use of sulprostone prior to vacuum aspiration, 359
    vacuum aspiration, 429
SIPPR-113(2 α,17 α-diethynyl-A-Nor-5α -androstane-2 β,17 β-diol-dihemisuccinate), antifertility effect (rat), 301
Socio-economic variables, effect on relative risk estimate of induced abortion, 637
Somatotropin level,
    effect of ethinyl estradiol + desogestrel, 97
    effect of triphasic ethinyl estradiol + levonorgestrel, 97
Species differences in sensitivity, GnRH agonist (mouse, rat, rabbit), 75
Sperm count,
    effect of gossypol (rat), 651
    effect of mating (rat), 217
    effect of polyvinylpyrrolidone-gossypol (rat), 651
Sperm motility,
    effect of chlorhexidine, 199
    effect of nonoxynol-9, 199
    effect of ORF 13904, 267
Sperm penetration test, effect of ORF 13904, 267
Spermatozoa, effect of intra-vas deferens injection of pH lowering polymer (monkey), 109
Styrene-maleic anhydride polymer, injection into vas deferens (monkey) 109
Subdermal implant contraceptive, levonorgestrel, 53, 163, 261, 623
Sulprostone (16-phenoxy- ω-17,18,19,20-tetranor-PGE_2 methyl sulfonylamide),
    effect on cervical dilatation, 359
    evaluation for termination of early pregnancy, 429
Suppressor/cytotoxic cells, effect of oral contraceptives, 377
Sustained release contraceptive formulations, measurement of release of incorporated steroids, 571
T lymphocytes, effect of oral contraceptives, 377
Termination, comparative study of contraceptive vaginal tablets, 445
Termination of early pregnancy, RU 486 + PGE analogue, 45
Termination rates, use of nonalkylated estrogen/progestogen compound in diabetic women, 23
Testis, effect of gossypol on macromolecular synthesis (rat), 661
Testis morphology,
    effect of gossypol (rat), 651
    effect of polyvinylpyrrolidone-gossypol (rat), 651
Testosterone release by Leydig cells, effect of gossypol (mouse), 275
Thyroid function,
    effect of ethinyl estradiol + desogestrel, 97
    effect of triphasic ethinyl estradiol + levonorgestrel, 97
Timing of insertion, effect on expulsion associated with immediate postpartum IUD insertions, 119
Transmembrane Migration Ratio method, use in sperm motility studies, 199

Triglycerides level,
effect of combined oral contraceptives, 223
effect of vasectomy, 149
Triphasic oral contraceptive, ethinylestradiol + norethindrone, 367
Trophoblast cells,
effect of anordrin, 301
effect of SIPPR-113, 301
Type of oral contraceptive components, effect on relative risk of breast cancer among oral contraceptive users, 553
United Nations Conference on Human Rights, 323
United Nations Fund for Population Activities, 323
United Nations International Conference on Population, 323
United Nations World Population Conference, 323
Urban population, projected, 1
Urinary and biliary metabolites of ethynylestradiol, 173
Uterine contractility,
effect of RU 486, 45
effect of RU 486 + PGE analogue, 45
Uterus,
effect of Centchroman (monkey), 483
effect of Hibiscus rosa-sinensis flowers (mouse), 517
UV-B light, effects of photodecomposition of norethisterone, 207
Vacuum aspiration,
effect of pretreatment with sulprostone, 359
evaluation for termination of early pregnancy, 429
Vagina, effect of Centchroman (monkey), 483
Vaginal contraceptive,
Emko vaginal tablets, 445
Neo Sampoon, 445
ORF 13904, 267
Ortho vaginal tablets, 445
Vaginal contraceptive activity, aryl 4-guanidinobenzoates (rabbit), 183
Vaginal contraceptive ring,
releasing levonorgestrel, 455, 581
releasing progesterone, 603
Vasectomy, effect on serum lipid levels, 149
Vasomotor symptoms, use of intranasal nafarelin acetate, 531
Viability of Leydig cells, effect of gossypol (mouse), 275
Vitamin status, effect of vitamin supplements with administration of ethinyl estradiol + d-norgestrel, 405
Vitamin supplements, effect on clinical and biochemical indices with administration of ethinyl estradiol + d-norgestrel, 405
Weight of breastfed infants,
effect of copper T 200, 603
effect of copper T 380 Ag, 53, 623
effect of levonorgestrel, 53, 623
effect of progsterone-releasing vaginal rings, 603
Weight of nursing women,
use of copper T 380 Ag, 623
use of Norplant® subdermal implants, 623
White blood cell count, effect of nafarelin acetate, 531
White blood cell count and differential, effect of norethisterone enanthate, 417
World Health Assembly (WHA), 323

CONTRACEPTION

World Health Organization Scientific Groups, 323
World Health Organization's Expanded Programme of Research, Development and Research Training in Human Reproduction, 323
World Health Organization's Special Programme of Research, Development and Research Training in Human Reproduction, 323
World population, projected, 1
Zygote transport, effect of *Hibiscus rosa-sinensis* flowers (mouse), 517